In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recombine, Inc.

https://recombine.com/

Latest From Recombine, Inc.

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Deals Market Intelligence

Deals In Depth: May 2016

Biogen signed a $2bn deal with UPenn focused on gene therapy; Thermo Fisher made its second major acquisition this year, paying over $4bn for FEI. Early-stage venture funding and FOPOs made up more than half of the month's total $1.6bn in biopharma financing, and big debt offerings from Wright Medical and Teleflex dominated device financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
UsernamePublicRestriction

Register